Journal
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Volume 33, Issue 6, Pages 1053-1063Publisher
ELSEVIER SCI LTD
DOI: 10.1006/jmcc.2001.1366
Keywords
SR Ca2+ ATPase; contractility; transgenic; gene therapy
Categories
Funding
- NHLBI NIH HHS [R01 HL 64140-02] Funding Source: Medline
Ask authors/readers for more resources
The control of intracellular calcium is central to regulation of cardiac contractility, A defect in SR Ca2+ transport and SR Ca2+ ATPase pump activity and expression level has been implicated as a major player in cardiac dysfunction, However, a precise cause-effect relationship between alterations in SERCA pump level and cardiac contractility could not be established from these studies. Progress in transgenic mouse technology and adenoviral gene transfer has provided new tools to investigate the role of SERCA pump level in the heart. This review focuses on how alterations in SERCA level affect Ca2+ homeostasis and cardiac contractility. It discusses the consequences of altered SERCA pump levels for the expression and activity of other Ca2+ handling proteins. Furthermore, the use of SERCA pump as a therapeutic target for gene therapy of heart failure is evaluated. (C) 2001 Academic Press.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available